A rheumatoid arthritis drug developed by Genentech proved to be effective in benefitting patients who have Covid-19-associated pneumonia, according to new late-stage clinical trial data.
Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.
The U.S. FDA approved Pfizer’s blockbuster drug Xeljanz to treat adults with moderate-to-severe active ulcerative colitis.
The U.S. Food and Drug Administration approved Pfizer Inc.’s second biosimilar to Johnson & Johnson’s blockbuster rheumatoid arthritis drug Remicade.
The FDA approved Boehringer Ingelheim Pharmaceuticals’ Cyltezo, a biosimilar to Humira, in a pre-filled syringe for treating chronic inflammatory diseases.
AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.
U.S. drugmaker AbbVie Inc. reported Q2 2017 earnings that edged past analysts’ expectations, helped by robust demand for the company’s flagship RA drug Humira.
Eli Lilly and Company and Incyte Corporation announced a new pooled analysis of data from eight Olumiant (baricitinib) clinical trials, showing that baricitinib-treated and placebo-treated patients with moderate-to-severe rheumatoid arthritis had similar rates of serious infection incidents.
Janssen-Cilag International NV today announced long-term results from SIRROUND-T, a pivotal Phase 3 study that showed sirukumab improved the signs and symptoms of moderately to severely active rheumatoid arthritis (RA) through 52 weeks of treatment in adult patients with an inadequate response and/or intolerance to anti-tumor necrosis factor (TNF)-alpha treatments.
AbbVie’s rheumatoid arthritis drug was superior to a placebo in a late-stage study involving patients that have not responded adequately to standard treatments.